Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons
Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2021
|
| _version_ | 1797107629500137472 |
|---|---|
| author | Ramanathan, S Tseng, M Davies, AJ Uy, CE Paneva, S Mgbachi, VC Michael, S Varley, JA Binks, S Themistocleous, AC Fehmi, J Anziska, Y Soni, A Hofer, M Waters, P Brilot, F Dale, RC Dawes, J Rinaldi, S Bennett, DL Irani, SR |
| author_facet | Ramanathan, S Tseng, M Davies, AJ Uy, CE Paneva, S Mgbachi, VC Michael, S Varley, JA Binks, S Themistocleous, AC Fehmi, J Anziska, Y Soni, A Hofer, M Waters, P Brilot, F Dale, RC Dawes, J Rinaldi, S Bennett, DL Irani, SR |
| author_sort | Ramanathan, S |
| collection | OXFORD |
| description | Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, in both cohorts, normal nerve conduction studies and reduced intraepidermal nerve fiber densities were observed in the sampled patient subsets. In LGI1 antibody patients, pain responded to immunotherapy (p = 0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2 antibody patients (p = 0.019). Serum CASPR2 antibodies, but not LGI1 antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences that may underlie our clinical observations. |
| first_indexed | 2024-03-07T07:18:44Z |
| format | Journal article |
| id | oxford-uuid:ab513ee9-dc54-4141-9119-1a7009de46ff |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:18:44Z |
| publishDate | 2021 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:ab513ee9-dc54-4141-9119-1a7009de46ff2022-08-31T21:03:09ZLeucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisonsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ab513ee9-dc54-4141-9119-1a7009de46ffEnglishSymplectic ElementsWiley2021Ramanathan, STseng, MDavies, AJUy, CEPaneva, SMgbachi, VCMichael, SVarley, JABinks, SThemistocleous, ACFehmi, JAnziska, YSoni, AHofer, MWaters, PBrilot, FDale, RCDawes, JRinaldi, SBennett, DLIrani, SRPain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and identified as neuropathic in 89% versus 58% of these, respectively. Typically, in both cohorts, normal nerve conduction studies and reduced intraepidermal nerve fiber densities were observed in the sampled patient subsets. In LGI1 antibody patients, pain responded to immunotherapy (p = 0.008), often rapidly, with greater residual patient-rated impairment observed in CASPR2 antibody patients (p = 0.019). Serum CASPR2 antibodies, but not LGI1 antibodies, bound in vitro to unmyelinated human sensory neurons and rodent dorsal root ganglia, suggesting pathophysiological differences that may underlie our clinical observations. |
| spellingShingle | Ramanathan, S Tseng, M Davies, AJ Uy, CE Paneva, S Mgbachi, VC Michael, S Varley, JA Binks, S Themistocleous, AC Fehmi, J Anziska, Y Soni, A Hofer, M Waters, P Brilot, F Dale, RC Dawes, J Rinaldi, S Bennett, DL Irani, SR Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title | Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title_full | Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title_fullStr | Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title_full_unstemmed | Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title_short | Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons |
| title_sort | leucine rich glioma inactivated 1 versus contactin associated protein like 2 antibody neuropathic pain clinical and biological comparisons |
| work_keys_str_mv | AT ramanathans leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT tsengm leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT daviesaj leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT uyce leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT panevas leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT mgbachivc leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT michaels leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT varleyja leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT binkss leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT themistocleousac leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT fehmij leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT anziskay leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT sonia leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT hoferm leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT watersp leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT brilotf leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT dalerc leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT dawesj leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT rinaldis leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT bennettdl leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons AT iranisr leucinerichgliomainactivated1versuscontactinassociatedproteinlike2antibodyneuropathicpainclinicalandbiologicalcomparisons |